Upcoming Earnings Report for Krystal Biotech
Krystal Biotech KRYS is preparing to announce its quarterly earnings report. As anticipation builds, it's crucial for investors to stay informed about what to expect as the announcement draws near.
Analyst Earnings Estimates
Analysts project that Krystal Biotech will declare an earnings per share (EPS) of $1.29. Shareholders are hoping that the company will not only surpass this estimate but also provide optimistic growth forecasts for future quarters.
Importance of Guidance in Earnings Reports
When it comes to stock prices, it’s not only about beating or missing earnings estimates. Often, the guidance shared during earnings calls can have a bigger impact. Investors should be on the lookout for any positive direction provided for subsequent quarters.
Earnings History Overview
In the last reported quarter, Krystal Biotech missed its EPS target by $0.32, leading to a decline of 1.91% in share value the following day. This highlights how sensitive the market can be to earnings reports.
Performance Trend
Historically, the notable price changes after earnings releases can shift stock sentiments. Understanding past performances could give insights on how the stock may react this quarter.
Market Performance of Krystal Biotech's Stock
As of the last trading day, shares of Krystal Biotech were priced at $153.87. Throughout the past 52 weeks, there has been a 12.3% decline in stock value. Given this trend, long-term investors may feel cautious approaching this earnings release.
Analyst Ratings and Market Sentiment
Staying in the loop about market sentiment is critical for investors. Current analysis indicates a consensus rating of Buy on Krystal Biotech, buoyed by ten analyst ratings. With an average one-year price target of $206.0, this reflects a potential upside of 33.88%.
Comparison with Industry Peers
Taking a deeper look into peer analysis, we can see how Krystal Biotech stands against some key competitors such as ADMA Biologics and ACADIA Pharmaceuticals. Understanding relative performance helps investors gauge market positioning.
Financial Metrics of Peers
Analyzing the financial health of similar companies can also provide context for Krystal Biotech's prospects:
- ADMA Biologics has a consensus rating of Buy with a one-year price target around $32.0, indicating possible volatility.
- Alkermes presents a potential target of $44.0, also marked as Buy from analysts.
- ACADIA Pharmaceuticals has a different outlook, with a target suggesting a downturn.
Insights on Krystal Biotech
Krystal Biotech Inc is dedicated to pioneering innovative gene therapies aimed at tackling serious health issues. Their proprietary STAR-D platform allows them to create unique solutions tailored to specific dermatological conditions. The company is committed to expanding its offerings into broader dermatological needs in the future.
Current Financial Landscape
Market Capitalization: The market capitalization of Krystal Biotech remains below industry averages, which may affect investor sentiment. Various factors such as growth potential and operational scalability are worth noting in this respect.
Revenue Growth: The most recent quarterly report indicated a remarkable revenue growth rate of approximately 94.88%. This performance places Krystal Biotech well ahead of most competitors in the healthcare sector.
Profit Margins: The company's net margin reaches 40.52%, showcasing strong financial management and efficiency.
Management of Debt: Krystal Biotech's approach to debt remains conservative, maintaining a minimal debt-to-equity ratio of 0.01.
Frequently Asked Questions
What is the expected EPS for Krystal Biotech?
The expected EPS for Krystal Biotech is projected to be $1.29.
How did Krystal Biotech perform in the last quarter?
In the last quarter, Krystal Biotech missed its EPS target by $0.32, causing a decrease in share price.
What is the current stock price for Krystal Biotech?
The last trading price for Krystal Biotech was $153.87.
What is the analyst consensus rating for Krystal Biotech?
The consensus rating for Krystal Biotech is currently Buy.
How does Krystal Biotech compare to its peers?
Krystal Biotech is currently leading in revenue growth compared to its peers, although its market capitalization remains smaller.
